Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login